Marco Cattaneo

Prof. Dr. Marco Cattaneo

orcid

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in JACC
Verified
Journal Article
Closed access
LBLaurent Bonello
Laurent Bonello
UTUdaya S. Tantry
Udaya S. Tantry
RMRosella Marcucci
Rosella Marcucci
RBRuediger Blindt
Ruediger Blindt
DADominick J. Angiolillo
Dominick J. Angiolillo
PGPaul A. Gurbel
Paul A. Gurbel

10 April 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MCMarco Cattaneo
Marco Cattaneo
CCChiara Cerletti
Chiara Cerletti
PHPaul Harrison
Paul Harrison
CHC. P. M. Hayward
C. P. M. Hayward
DKD. Kenny
D. Kenny
AMA. D. Michelson
A. D. Michelson
Click on the article title to read more.

1 July 1994 in Circulation
Verified
Journal Article
Closed access
PMP A Merlini
P A Merlini
KBK A Bauer
K A Bauer
LOL Oltrona
L Oltrona
DAD Ardissino
D Ardissino
MCMarco Cattaneo
Marco Cattaneo
RRR D Rosenberg
R D Rosenberg
BACKGROUND: The blood coagulation system is activated in the acute phase of unstable angina and acute myocardial infarction. However, it remains unclear whether augmented function of the hemostatic mechanism serves only as a marker of the acute thrombotic episode or whether a hypercoagulable state persists for a prolonged period after clinical stabilization. METHODS AND RESULTS: We prospectively measured the plasma concentrations of prothrombin fragment 1 + 2 (F1 + 2) and fibrinopeptide A (FPA) in consecutive patients presenting with unstable angina (n = 81) or acute myocardial infarction (n = 32), respectively. At 6 months, plasma determinations were repeated in patients experiencing an uneventful clinical course (unstable angina, n = 57; myocardial infarction, n = 23). We quantitated the plasma levels of F1 + 2 and FPA in control patients with stable angina (n = 37) or healthy individuals (n = 32) who were matched for age and sex. The median plasma concentrations of F1 + 2 and FPA are significantly higher in patients presenting with unstable angina (F1 + 2, 1.08 nmol/L; FPA, 2.4 nmol/L) or acute myocardial infarction (F1 + 2, 1.27 nmol/L; FPA, 3.55 nmol/L) compared with patients with stable angina (F1 + 2, 0.74 nmol/L; FPA, 1.3 nmol/L; P < .0001) or healthy individuals (F1 + 2, 0.71 nmol/L; FPA, 0.80 nmol/L; P < .0001). At 6 months, the median plasma levels of F1 + 2 in patients exhibiting an uneventful clinical course did not differ from values obtained at admission (unstable angina, 1.26 versus 1.07 nmol/L, P = NS; myocardial infarction, 1.22 versus 1.29 nmol/L, P = NS), whereas the median plasma levels of FPA in the same two subpopulations were significantly reduced (unstable angina, 1.1 versus 2.9 nmol/L, P = .0003; myocardial infarction, 1.1 versus 3.0 nmol/L; P = .0028). CONCLUSIONS: During the acute phase of unstable angina and myocardial infarction, patients exhibit increased coagulation system activity. Over the next 6 months, patients with unstable angina or myocardial infarction experiencing an uneventful clinical course manifest a persistent hypercoagulable state with minimal generation of fibrin.

1 November 2004 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
MCMarco Cattaneo
Marco Cattaneo
Aspirin and the thienopyridines ticlopidine and clopidogrel are antiplatelet agents that display good antithrombotic activity. In the past few years, the concept of aspirin resistance has been largely emphasized in the medical literature, although its definition is still uncertain. I suggest that “aspirin-resistant” should be considered as a description for those individuals in whom aspirin fails to inhibit thromboxane A 2 production, irrespective of the results of unspecific tests of platelet function, such as the bleeding time, platelet aggregation, or the PFA-100 system. Less well known than aspirin resistance, but certainly better characterized, is the issue of “clopidogrel resistance,” which is probably mostly caused by inefficient metabolism of the prodrug clopidogrel to its active metabolite. At present, aspirin and clopidogrel resistance should not be looked for in the clinical setting, because there is no definite demonstration of an association with clinical events conditioning cost-effective changes in patient management.

13 January 2006 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
CHC. P. M. Hayward
C. P. M. Hayward
PHP. Harrison
P. Harrison
MCMarco Cattaneo
Marco Cattaneo
TOT. L. Ortel
T. L. Ortel
ARA. K. Rao
A. K. Rao
THTHE PLATELET PHYSIOLOGY SUBCOMMITTEE OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS
THE PLATELET PHYSIOLOGY SUBCOMMITTEE OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS
Summary. Background: Closure time (CT), measured by platelet function analyzer (PFA‐100®) device, is now available to the clinical laboratory as a possible alternative or supplement to the bleeding time test. Aim: On behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH‐SSC), a working Group was formed to review and make recommendations on the use of the PFA‐100 CT in the evaluation of platelet function within the clinical laboratory. Methods: The Medline database was searched to review the published information on the PFA‐100 CT in the evaluation of platelet disorders and platelet function. This information, and expert opinion, was used to prepare a report and generate consensus recommendations. Results: Although the PFA‐100 CT is abnormal in some forms of platelet disorders, the test does not have sufficient sensitivity or specificity to be used as a screening tool for platelet disorders. A role of the PFA‐100 CT in therapeutic monitoring of platelet function remains to be established. Conclusions: The PFA‐100 closure time should be considered optional in the evaluation of platelet disorders and function, and its use in therapeutic monitoring of platelet function is currently best restricted to research studies and prospective clinical trials.

1 June 2014 in JACC
Verified
Journal Article
Closed access
MCMarco Cattaneo
Marco Cattaneo
Rainer SchulzRainer Schulz
Rainer Schulz
SNSven Nylander
Sven Nylander